May 25, 2017
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
Read More
January 29, 2017
FDA Grants Priority Review Designation for Actemra in Giant Cell Arteritis
Read More
November 21, 2016
Genentech’s New Giant Cell Arteritis Drug Shows Majority of Users Achieved Steroid-Free Disease Remission at One Year
Read More
June 18, 2016
Genentech Phase III Study Shows Actemra Effective at Maintaining Steroid-Free Remission in Patients with Giant Cell Arteritis
Read More
X